Yescarta made in Cina

New "cell factory" for cancer treatment launched in Shanghai

A factory for the development of human immune cells has been launched in Shanghai in order to provide personalized therapy for patients with certain types of cancer, reports Chinese Internet Information Center.

Fosun Kite Biotechnology, a joint venture between China and the United States, will produce the drug Yescarta, the first in the world to use CAR-T technology for the treatment of certain types of B-cell lymphomas.

The enterprise, located in Zhangjiang Hi-Tech Park, is expected to reach commercial production capacity by 2020.

CAR-T cell therapy technology genetically modifies the patient's own T cells, which allows them to better recognize and attack cancer cells. Such therapy is seen as a revolution in cancer treatment research.

However, cell therapy is expensive, the cost of its passage in the United States is $ 373 thousand. It is assumed that the new Chinese factory will reduce prices for Chinese patients.

"We hope that local production will significantly reduce costs and give Chinese patients faster access to the drug," he said Wu Yifang, Chairman of the Management Board of Fosun Kite.

Portal "Eternal youth" http://vechnayamolodost.ru